Novartis AG ADR is a drug manufacturers - general business based in the US. Novartis AG ADR shares (NVS) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $103.09 – a decrease of 0.3% over the previous week. Novartis AG ADR employs 76,057 staff and has a trailing 12-month revenue of around $49.9 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $103.09 |
|---|---|
| 52-week range | $91.22 - $120.92 |
| 50-day moving average | $113.40 |
| 200-day moving average | $106.47 |
| Wall St. target price | $116.16 |
| PE ratio | 18.1086 |
| Dividend yield | $3.919 (3.64%) |
| Earnings per share (TTM) | $5.71 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $103.27 from 2024-11-19
| 1 week (2024-11-14) | -0.13% |
|---|---|
| 1 month (2024-10-21) | -10.77% |
| 3 months (2024-08-21) | -12.19% |
| 6 months (2024-05-21) | 0.42% |
| 1 year (2023-11-21) | 7.15% |
|---|---|
| 2 years (2022-11-21) | 36.56% |
| 3 years (2021-11-19) | 51.58% |
| 5 years (2019-11-21) | 48.01% |
Valuing Novartis AG ADR stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Novartis AG ADR's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Novartis AG ADR's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Novartis AG ADR shares trade at around 18x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Novartis AG ADR's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.0793. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Novartis AG ADR's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Novartis AG ADR's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $21 billion.
The EBITDA is a measure of a Novartis AG ADR's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $49.9 billion |
|---|---|
| Operating margin TTM | 33.47% |
| Gross profit TTM | $36.7 billion |
| Return on assets TTM | 10.59% |
| Return on equity TTM | 28.79% |
| Profit margin | 35.25% |
| Book value | $21.67 |
| Market Capitalization | $209.3 billion |
TTM: trailing 12 months
Dividend payout ratio: 51.32% of net profits
Recently Novartis AG ADR has paid out, on average, around 100% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Novartis AG ADR shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Novartis AG ADR's case, that would currently equate to about $3.919 per share.
Novartis AG ADR's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Novartis AG ADR's most recent dividend payout was on 18 April 2024. The latest dividend was paid out to all shareholders who bought their shares by 6 March 2024 (the "ex-dividend date").
Novartis AG ADR's shares were split on a 1116:1000 basis on 8 April 2019 . So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1116 shares. This wouldn't directly have changed the overall worth of your Novartis AG ADR shares – just the quantity. However, indirectly, the new 10.4% lower share price could have impacted the market appetite for Novartis AG ADR shares which in turn could have impacted Novartis AG ADR's share price.
Over the last 12 months, Novartis AG ADR's shares have ranged in value from as little as $91.2246 up to $120.92. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Novartis AG ADR's is 0.505. This would suggest that Novartis AG ADR's shares are less volatile than average (for this exchange).
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.